Christopher Bunick, MD, PhD, reviews data on investigational atopic dermatitis agents presented at EADV 2026 and biomarker ...
The US Food and Drug Administration (FDA) has approved pritelivir (HOVILPRI; Asahi Kasei Therapeutics) 100-mg tablets for the ...
Galderma announced an agreement to acquire ZO Skin Health for an enterprise value of $1.5 billion, a move designed to expand ...
Remibrutinib is approved for chronic spontaneous urticaria (CSU) and most recently, symptomatic dermographism, with the label ...
In "Recognizing EPP: Diagnostic Red Flags, Psychosocial Burden, and Confirmatory Workup," Dr. Bonkovsky turns to what should ...
A patient with 45 percent hair loss and a wedding in six months illustrates why psychosocial burden can reclassify disease ...
An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about ...
In "Case 2: Escalating Therapy After Biologic Failure in HS," the panel shifts to the series' second patient case.
Sitryx Therapeutics announced positive topline results from a Phase 1b trial of SYX-5219, a first-in-class oral pyruvate ...
Adults with chronic hand eczema (CHE) treated within the Duke University Health System reported substantial work productivity ...
Dr. Singh stresses that tolerability is key to achieving good outcomes with hedgehog inhibitors. Baseline and periodic ...
Cosibelimab (Unloxcyt; Sun Pharma), a PD-L1 inhibitor, is also approved for locally advanced and metastatic cutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results